The Society of Surgical Oncology, inc.
The American Society of Breast Surgeons.
Annals of Surgical Oncology

Log in | Register

Erratum to: Axillary Recurrence Rate Following Negative Sentinel Node Biopsy for Invasive Breast Cancer: Long-Term Follow-Up

John V. Kiluk MD, Quan P. Ly MD, Alfredo A. Santillan MD, MPH, Tammi Meade BS, Daniel Ramos BS, Douglas S. Reintgen MD, Sophie Dessureault MD, PhD, Michelle Davis BS, Corinne Shamehdi BS, Charles E. Cox MD
Erratum
Volume 17, Issue 2 / February , 2009

Abstract

Objective

Sentinel lymph node (SLN) biopsy has replaced axillary lymph node dissection (ALND) as the staging procedure for breast cancer. SLN biopsy causes less morbidity and is more cost effective than complete ALND. Lymphatic mapping and SLN biopsy have a low false-negative rate, but long-term outcomes in large consecutive series of patients are unavailable.

Methods

Retrospective review of a prospectively accrued institutional breast cancer database was performed. The initial mapping of 1,528 patients with invasive breast cancer that demonstrated negative sentinel node biopsy and no axillary dissection in 1,530 cases between January 1995 and June 2003 were collated and reviewed to achieve a long-term follow-up. These 1,528 patients were reviewed for follow-up time, local recurrences, distant metastases, and survival.

Results

A total of 1,530 consecutively mapped invasive breast cancer cases had negative SLN biopsy and no ALND. The mean invasive tumor size of was 1.40 cm. Of patients, 1,212 (79.2%) underwent lumpectomy and 318 (20.8%) underwent mastectomy. Median follow-up was 63 months (range 0.1–144 months). There have been 4 (0.26%) cases presenting with local axillary recurrences, 54 (3.53%) cases presenting with local recurrences in the ipsilateral breast/chest wall, and 24 (1.57%) cases presenting with distant metastases.

Conclusion

These data confirm that SLN biopsy is an effective and safe alternative to ALND for detection of nodal metastases in patients with invasive breast cancer and validates its use as the standard tool for nodal staging.

Add a comment



0 comment(s)

Special Announcement:             NEW IMPACT FACTOR OF 4.130

The 2009 Impact Factor for Annals of Surgical Oncology has risen to 4.130. The journal is now ranked 6 of 166 journals publishing in Thomson Reuters' (formerly ISI) subject category "Surgery," making it the top ranked oncology journal in surgery.

 

HIGHLIGHTED VIDEO OF THE MONTH

Liver Resection with Portal Vein Thrombectomy for Hepatocellular Carcinoma With Vascular Invasion

Luca Aldrighetti MD, Carlo Pulitanò MD, Marco Catena MD, Marcella Arru MD, Eleonora Guzzetti MD, Jane Halliday MD, Gianfranco Ferla MD